593 related articles for article (PubMed ID: 27822685)
1. Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE; Antonarakis ES
Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
[TBL] [Abstract][Full Text] [Related]
2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Galletti G; Leach BI; Lam L; Tagawa ST
Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
[TBL] [Abstract][Full Text] [Related]
5. Current therapeutic options in metastatic castration-resistant prostate cancer.
Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
7. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
8. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of metastatic, castration-resistant prostate cancer].
von Amsberg G; Merseburger AS
Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
[TBL] [Abstract][Full Text] [Related]
11. Sequencing of agents for castration-resistant prostate cancer.
Hurwitz M; Petrylak DP
Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
[TBL] [Abstract][Full Text] [Related]
12. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
13. [Current treatment concepts for castration resistant prostate cancer].
von Amsberg G; Stroelin P; Bokemeyer C; Steuber T
Dtsch Med Wochenschr; 2014 Oct; 139(41):2086-90. PubMed ID: 25268211
[TBL] [Abstract][Full Text] [Related]
14. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
Liu JJ; Zhang J
Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
[TBL] [Abstract][Full Text] [Related]
15. Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Vaishampayan UN
Curr Opin Oncol; 2015 May; 27(3):201-8. PubMed ID: 25811344
[TBL] [Abstract][Full Text] [Related]
16. Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.
Maroto P; Solsona E; Gallardo E; Mellado B; Morote J; Arranz JÁ; Gómez-Veiga F; Unda M; Climent MÁ; Alcaraz A
Crit Rev Oncol Hematol; 2016 Apr; 100():127-36. PubMed ID: 26363809
[TBL] [Abstract][Full Text] [Related]
17. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
18. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
Nussbaum N; George DJ; Abernethy AP; Dolan CM; Oestreicher N; Flanders S; Dorff TB
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):111-21. PubMed ID: 26832363
[TBL] [Abstract][Full Text] [Related]
19. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
Dreicer R
Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
[TBL] [Abstract][Full Text] [Related]
20. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
